ANA Investigates

The latest in neurology and neuroscience, each month from the ANA.

ANA members are offered the opportunity to claim AMA PRA Category 1 Credits™. Detailed information about CME is on OnDEC.

Listen to ANA Investigates here or on your podcast application of choice. To receive automatic updates when new episodes are released, subscribe on Apple | Google | Spotify

Submit Ideas for Future Episodes

Access CME

View Episode Archive

Latest episode

ANA Investigates MMA Embolization

This month we're focusing on Chronic Subdural Hematoma, where a minimally invasive strategy called Middle Meningeal Artery Embolization is offering expanded treatment options for select patients.
Episode Description

2024 has been a year of exciting trials on minimally invasive techniques in intracranial hemorrhage. This month we're focusing on Chronic Subdural Hematoma, where a minimally invasive strategy called Middle Meningeal Artery (MMA) Embolization is offering expanded treatment options for select patients. Dr. Chris Kellner is a cerebrovascular neurosurgeon and associate professor of neurosurgery at Mount Sinai. He'll talk about the promise of MMA embolization with Dr. Sarah Nelson, neurointensivist and neurohospitalist at Tufts Medical Center. We'll have more on these trials on the podcast in our June episode as well, with a focus next month on Minimally Invasive Techniques in Spontaneous Intracerebral Hemorrhage. Series 5, Episode 8

Featuring
  • Guest: Dr. Chris Kellner, Mount Sinai
  • Interviewer/Producer: Dr. Sarah Nelson, Tufts Medical Center
Disclosures

Dr. Kellner is the PI for two studies discussed during the podcast funding was received from Medtronic and Cerenovus.

Read Full Episode Description

ANA Investigates Neuroprognostication After Cardiac Arrest: Nihilism vs. Over Optimism

Football fans may remember in January 2023 when Damar Hamlin, a player for the Buffalo Bills, suffered a cardiac arrest and collapsed on the field during a game on live television. He had a remarkable neurologic recovery, prompting us to focus..
Episode Description

Football fans may remember in January 2023 when Damar Hamlin, a player for the Buffalo Bills, suffered a cardiac arrest and collapsed on the field during a game on live television. He had a remarkable neurologic recovery, prompting us to focus our podcast that month on the need to avoid nihilism when we prognosticate after cardiac arrest. But what is the right balance between pessimism and optimism? Today, we'll hear from Dr. Karen Hirsch, neuro intensivist and associate professor of neurology at Stanford, about finding the Goldilocks zone in neuro prognostication after cardiac arrest. Dr. Hirsch was interviewed by Dr. Sarah Stern-Nezer, vascular neurologist and neuro intensivist at UC Irvine. Series 5, Episode 7

Featuring
  • Guest: Dr. Karen Hirsch, Stanford Health Care
  • Interviewer/Producer: Dr. Sara Stern-Nezer, University of California, Irvine
Disclosures

None

Read Full Episode Description

ANA Investigates Advanced Therapies for Glioblastoma

Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Our guest today is Dr. Eric Wong from Brown University, an international expert on advanced treat....
Episode Description

Glioblastoma is the most common malignant brain tumor and one of the most aggressive solid tumors. Much progress has been made in the understanding and classification of gliomas, but progress in terms of prolonging survival has been limited. Several recent investigational therapies are bringing new hope. Our guest today is Dr. Eric Wong from Brown University. He is an international expert on advanced treatments for glioblastoma and a Professor of Medicine, Radiation Oncology, Neurosurgery, and Neurology at Brown University. He was interviewed by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at Brown. Series 5, Episode 6

Featuring
  • Guest: Dr. Eric Wong, Brown University
  • Interviewer/Producer: Dr. Christoph Stretz, Brown University
Disclosures

 

Eric T Wong, MD conducts clinical trials and serves on an advisory board sponsored by Novocure. Dr. Wong also serves on DSMB for Turning Point Therapeutics & Bristol Myers Squibb, and conducts clinical trials for AstraZeneca, Daiichi Sankyo, Imvax, MimiVax, Oblato, Ono Pharmaceuticals, Orbus, and Regeneron.

Read Full Episode Description

ANA Investigates Updated Brain Death Determination Guidelines

Brain death is one of the most controversial and ethically complex topics in neurology, but it's a regular part of our clinical practice. Late last year, a new set of guidelines was published that address some of the thorniest technical and e...
Episode Description

Brain death is one of the most controversial and ethically complex topics in neurology, but it's a regular part of clinical practice. Late last year, a new set of guidelines was published that address some of the thorniest technical and ethical issues in the clinical determination of brain death. Unlike previous guidelines, the 2023 update addresses brain death determination in both adults and children. The guidelines were published by the American Academy of Neurology, the American Academy of Pediatrics, the Child Neurology Society, and the Society of Critical Care Medicine. Two of their authors join us today to discuss the changes, and best practices for communicating this information to families. Dr. Ariane Lewis is a professor in the departments of Neurology and Neurosurgery, and the director of the Division of Neurocritical Care at NYU Langone Medical Center. And Dr. Matthew Kirschen is an assistant professor of Anesthesiology and Critical Care at the hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. They were interviewed by Dr. Masoom Desai of the University of New Mexico.

Featuring
  • Guest: Dr. Ariane Lewis, NYU Langone Medical Center
  • Guest: Dr. Matthew Kirschen, University of Pennsylvania and the Children's Hospital of Philadelphia
  • Interviewer/Producer: Dr. Masoom Desai, University of New Mexico
Disclosures

None

Read Full Episode Description

ANA Investigates Auto-Antibodies for Small Fiber Neuropathy

Small fiber neuropathy is one of those conditions in neurology that can feel frustratingly intangible, and in about half of cases, the usual lab testing doesn't reveal a cause. In this episode of ANA Investigates, host Adeline Goss discusses the
Episode Description

Small fiber neuropathy is one of those conditions in neurology that can feel frustratingly intangible. Even for patients with severe neuropathic pain and autonomic symptoms, in about half of cases, the usual lab testing doesn't reveal a cause. There's increasing evidence that autoimmunity may be a factor in some of these cases of idiopathic small fiber neuropathy, but how to test and who to treat with immunosuppression is less clear. Our guest today, Anne Louise Oaklander, is an Associate Professor of Neurology at Massachusetts General Hospital and an Assistant in Neuropathology. She's known for her work on small fiber neuropathies and in this episode we'll talk about new autoantibodies associated with small fiber neuropathy and where we are in treating this challenging condition.

Featuring
  • Guest: Dr. Anne Louise Oaklander, Massachusetts General Hospital
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

None

Read Full Episode Description

ANA Investigates the Clinical Implementation of Lecanemab for Alzheimer's Dementia

Now that lecanemab is being administered in clinics across the country - how is it changing the lives of people with Alzheimers and their families?
Episode Description

The recent FDA approval of lecanemab, an amyloid-sequestering agent, has been hailed as a breakthrough in the treatment of Alzheimer disease. Critics of the drug have pointed to its cost, risks, and treatment burden. Now that lecanemab is being administered in clinics across the country - how is it changing the lives of people with Alzheimers and their families? Dr. Megan Richie, neurohospitalist at UCSF, spoke to Dr. Seth A. Gale, Co-Director of the Brain Health Program and Assistant Professor of Neurology at Harvard Medical School. Dr. Gale has been involved in creating the clinical program that is delivering lecanemab to patients at Brigham and Women’s Hospital and Massachusetts General Hospital, with the first patients receiving the drug this month. Series 5, Episode 3

Featuring
  • Guest: Dr. Seth Gale, Harvard Medical School
  • Interviewer/Producer: Dr. Megan Richie, UCSF
  • Interviewer/Producer: Dr. Masoom Desai, University of New Mexico
Disclosures

Dr. Gale disclosed that he is a site Principal Investigator or Sub-Investigator (at Brigham and Women's Hospital) for several clinical trials in Alzheimer disease. Sponsors for those studies include Biogen, Eisai, Roche, Genentech, and Eli Lilly. I am on a scientific advisory board for MindAhead DE, with the opportunity for honoraria.

Read Full Episode Description

ANA Investigates Chronic Pain

Chronic pain can be incredibly challenging -- for patients, of course, and also for their physicians. On this episode of ANA investigates, Dr. Adeline Goss talks to Dr. Prasad Shirvalkar of UCSF about a new possible strategy for treating chronic
Episode Description

 

Chronic pain can be incredibly challenging -- for patients, of course, and also for their physicians. On this episode of ANA investigates, Dr. Adeline Goss talks to Dr. Prasad Shirvalkar of UCSF about a new possible strategy for treating chronic pain: deep brain stimulation.

Featuring
  • Guest: Dr. Prasad Shirvalkar, UCSF
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

Dr. Shirvalkar disclosed that Medtronic Inc, donated devices for research, but no direct financial support.

Read Full Episode Description

ANA Investigates The Neurovasculome

The brain and its vasculature used to be considered separate domains. But in the last decade, we’ve learned more about the interplay between brain cells and vascular cells. Pathological studies are revealing a surprising degree of overlap ...
Episode Description

The brain and its vasculature used to be considered separate domains. But in the last decade, we’ve learned more about the interplay between brain cells and vascular cells. Pathological studies are revealing a surprising degree of overlap between cerebrovascular disease and neurodegenerative disease. All of this has led to the coining of a new word: the neurovasculome. Our guest today is Dr. Eric Smith, an author of a recent scientific statement about the neurovasculome in the journal Stroke. Dr. Smith is a Professor of Neurology, Radiology, and Community Health Sciences at the University of Calgary, and the holder of the endowed Kathy Taylor Chair in Vascular Dementia. He was interviewed about the neurovasculome by Dr. Christoph Stretz, a Vascular and Critical Care neurologist at the Warren Alpert Medical School of Brown University. Series 5, Episode 1

Featuring
  • Guest: Dr. Eric Smith, University of Calgary
  • Interviewer/Producer: Dr. Christoph Stretz, Brown University
Disclosures

 

Disclosures: Dr. Smith disclosed that he receives personal consulting fees from Alnylam Pharmaceuticals and Eli Lilly

Read Full Episode Description

*Bonus Episode* ANA Investigates ANA2023!

148th Annual Meeting Highlights
As the ANA's 2023 Annual Meeting comes to a close, we wanted to catch up with Frances Jensen and Rebecca Gottesman...
Episode Description

As the ANA's 2023 Annual Meeting comes to a close, we wanted to catch up with Frances Jensen Chair of the Department of Neurology at University of Pennsylvania and outgoing President of the ANA, and Rebecca Gottesman, Stroke Branch Chief of the National Institute of Neurological Disorders and Stroke and outgoing Chair of the Annual Meeting Planning Committee. Listen as these two leaders chat about the cutting-edge research, exciting sessions, and broader themes that have defined this year's meeting in Philadelphia.

Featuring
  • Interviewer/Producer: Dr. Frances Jensen, University of Pennsylvania
  • Guest: Dr. Rebecca Gottesman, National Institute of Neurological Disorders and Stroke
Disclosures

No relevant relationships

Read Full Episode Description

ANA Investigates Insomnia and Stroke

A growing body of research suggests that people with insomnia are at higher risk of stroke. Listen today as we dive into how sleep health, stroke, and the nervous system all have an affect on each other.
Episode Description

 

A growing body of research suggests that people with insomnia are at higher risk of stroke. Listen today as we dive into how sleep health, stroke, and the nervous system all have an affect on each other.

Featuring
  • Guest: Dr. Sonja Schuetz, University of Michigan
  • Interviewer/Producer: Dr. Joseph Carerra, University of Michigan
Disclosures

Dr. Schuetz reports funding from contracts between University of Michigan and Oura Health Ltd., Huxley Medical Inc., and Apple Inc.

Read Full Episode Description

ANA Investigates Fetal Therapy

A recent study reported in the New England Journal of Medicine reviews enzyme replacement therapy given to a fetus with Pompe disease, for the first time, in an attempt to treat the disease before it does any serious damage.
Episode Description

 

Lysosomal storage diseases are progressive, inherited disorders of metabolism, many with devastating effects on the nervous system. Some of these diseases, like Infantile-Onset Pompe disease, can be treated to some degree in childhood by giving back the missing enzyme - a strategy called enzyme replacement therapy, or ERT. But a recent study reported in the New England Journal of Medicine goes a step farther -- by giving enzyme replacement therapy to a fetus with Pompe disease, for the first time, in an attempt to treat the disease before it does any serious damage. The paper’s first author is Dr. Jennifer Cohen, a Pediatric Medical Genetics Physician-Scientist at Duke University Health System. During this episode, she’ll walk us through the potential benefits of in-utero enzyme replacement therapy and other cutting-edge approaches to treating genetic neurologic conditions. A relatively new field called fetal therapy. Dr. Cohen was interviewed by Dr. Adeline Goss, the host of ANA Investigates. Series 4, Episode 10

Featuring
  • Guest: Dr. Jennifer Cohen, Duke University Health System
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

Dr. Cohen is a consultant with Bayer.

Read Full Episode Description

ANA Investigates Parkinsons and Environmental Toxins

A recent study in JAMA Neurology found an association between contaminated water at a military base in the 1970s-80s and the risk of Parkinson’s disease in military service members. What do we know about Parkinson’s and environmental toxins? Ser
Episode Description

 

A recent study in JAMA Neurology found an association between contaminated water at a military base in the 1970s-80s and the risk of Parkinson’s disease in military service members. What do we know about Parkinson’s and environmental toxins? Series 4, Episode 9

Featuring
  • Guest: Dr. Ray Dorsey, University of Rochester
  • Interviewer/Producer: Dr. Sara Stern-Nezer, UC Irvine
Disclosures

This episode does not award CME credit.

Read Full Episode Description

ANA Investigates Gut-Brain Axis

The nature of this so-called “gut-brain axis” -- the extent to which bacteria might actually shape brain function and disease -- is the topic of our show today.
Episode Description

There are trillions of bacteria living inside each of our gastrointestinal tracts and there’s growing evidence that those bacteria communicate with the brain. Some researchers are even hopeful that drugs targeted at the gut microbiome could help treat diseases as diverse as Parkinson’s disease, multiple sclerosis, or autism. The nature of this so-called “gut-brain axis” -- the extent to which bacteria might actually shape brain function and disease -- is the topic of our show today. Dr. Sarkis Mazmanian is the Luis and Nelly Sooks Professor of Microbiology in the Division of Biology and Biological Engineering at Caltech. He’s the recipient of many awards, including a MacArthur Genius Grant, for his work on the gut microbiome axis. Series 4, Episode 8

Featuring
  • Guest: Dr. Sarkis Mazmanian, Caltech
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
  • Interviewer/Producer: Dr. Sara Stern-Nezer, UCI Health
Disclosures

Disclosures: Dr. Mazmanian disclosed the following relationships related to this podcast topic: Axial Therapeutics: Board member and Consultant, Nuanced Health: Board member and Consultant, and Seed Health: Board member. This episode does not award CME credit.

Read Full Episode Description

ANA Investigates Disruptive Technologies: The Future of Neurotechnology

Recently on the podcast we’ve been talking about neurotechnology -- devices that interface with the brain to treat disease, for example by restoring speech function in people with locked-in syndrome, or motor function in people with paralyzed...
Episode Description

Recently on the podcast we’ve been talking about neurotechnology -- devices that interface with the brain to treat disease, for example by restoring speech function in people with locked-in syndrome, or motor function in people with paralyzed limbs. But listen to the media, and you’ll also hear buzz about neurotechnology for healthy people... Series 4, Episode 7

Featuring
  • Guest: Philip Sabes, PhD, UCSF
  • Interviewer/Producer: Rohini Samudralwar, MD, University of Pennsylvania
Disclosures

This episode is non-CME.

Read Full Episode Description

ANA Investigates Thrombectomy in Patients with Large Ischemic Strokes

Among several highlights of the recent International Stroke Conference was new evidence supporting endovascular thrombectomy for patients with so-called “large core” ischemic strokes. In current practice, thrombectomy is considered for ....
Episode Description

 

Among several highlights of the recent International Stroke Conference was new evidence supporting endovascular thrombectomy for patients with so-called “large core” ischemic strokes. In current practice, thrombectomy is considered for patients with occlusions of the internal carotid or middle cerebral artery who are less than 24 hours since the last known well and have a small “core” of ischemia on non-contrast head CT or CT or MR perfusion imaging -- in other words, there’s radiographic evidence that only a small core of the brain has suffered permanent injury and a larger penumbra of tissue can be saved. SELECT-2 is a multicenter randomized controlled trial that examined whether patients with LARGE cores of ischemic tissue could ALSO benefit from thrombectomy. On our show today we have SELECT-2 principal investigator Dr. AM-rou sou-RAJ, who is also Professor of Neurology at Case Western Reserve University School of Medicine. He was interviewed by Dr. Michelle Johansen, vascular neurologist at Johns Hopkins University, about what the study results might mean for stroke care -- and stroke imaging -- going forward.

Featuring
  • Guest: Dr. Amrou Sarraj, Professor of Neurology, Case Western Reserve University School of Medicine, George M. Humphrey II Endowed Chair, University Hospitals Neurological Institute, Director, Comprehensive Stroke Center and Stroke Systems, University Hospitals
  • Interviewer/Producer: Dr. Michelle Johansen, Johns Hopkins Medicine
  • Interviewer/Producer: Dr. Joseph Carrera, University of Michigan
Disclosures

Dr. Sarraj discloses the following relationships: SELECT2 principal investigator - funded by Stryker Neurovascular with research grant to University Hospitals Cleveland Medical Center and UT McGovern Medical School SELECT principal investigator - funded by Stryker Neurovascular with research grant to UT McGovern Medical School Member, Speaker bureau and advisory board - Stryker Neurovascular Provided advisory services to AstraZeneca, Genentech and Lumosa Theraputics

Read Full Episode Description

ANA Investigates TBI and Sports Medicine

Concussion, or mild acute traumatic brain injury, is incredibly common -- 1 in 5 of adolescents report having suffered a concussion at some point in their lifetime (JAMA. 2021;325(17):1789-1791)... and an estimated 1 in 5 players of contact...
Episode Description

Concussion, or mild acute traumatic brain injury, is incredibly common -- 1 in 5 of adolescents report having suffered a concussion at some point in their lifetime (JAMA. 2021;325(17):1789-1791)... and an estimated 1 in 5 players of contact sports suffer a concussion each season. Sports neurologists are rare enough that most people suffering concussions are never seen by one. And general neurologists aren’t always well-trained to treat this condition, especially as the science of concussion is advancing. Our guest today, Dr. Jose Posas is a sports neurologist and residency program director at Ochsner Medical Center in New Orleans and he spoke to ANA producer Dr. Mandy Jagolino-Cole of The University of Texas Health Science Center at Houston about recent findings in concussion research and how we can apply that research at the bedside. Series 4, Episode 5.

Publication mentioned in the episode: McAllister TW, Broglio SP, Katz BP, Perkins SM, LaPradd M, Zhou W, McCrea MA; Concussion Assessment, Research and Education (CARE) Consortium. Characteristics and Outcomes of Athletes With Slow Recovery From Sport-Related Concussion: A CARE Consortium Study. Neurology. 2023 Jan 18:10.1212/WNL.0000000000206853. doi: 10.1212/WNL.0000000000206853. Epub ahead of print. PMID: 36653178. https://pubmed.ncbi.nlm.nih.gov/36653178/

Featuring
  • Guest: Dr. Jose Posas, Ochsner Medical Center
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, The University of Texas Health Science Center at Houston
Disclosures

none

Read Full Episode Description

ANA Investigates Neuroethics and Disruptive Technologies Part 2: You Read My Mind

On our December show, we talked about ethical issues surrounding brain-computer interfaces. We’ll pick up the topic again this month with a discussion about one type of brain-computer interface: neuroprosthetics.
Episode Description

 

On our December show, we talked about ethical issues surrounding brain-computer interfaces. We’ll pick up the topic again this month with a discussion about one type of brain-computer interface: neuroprosthetics. Our guest is Dr. Edward Chang, Professor and Chair of Neurological Surgery at the University of California San Francisco. Dr. Chang is an expert in brain mapping during neurosurgery, with the aim of preserving the brain areas responsible for language, speech, movement and emotion. His research focuses on neuro-prosthetics that can restore movement in people who are paralyzed and speech in people with speech disorders. As we’ll talk about today, this research raises interesting ideas about the neural representation of speech and language and the ethics surrounding brain-computer interfaces. Dr. Chang was interviewed by ANA Producer Dr. Amanda Jagolino-Cole of The University of Texas Health Science Center at Houston. Series 4, Episode 4. 

Featuring
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, The University of Texas Health Science Center at Houston, McGovern Medical School
  • Guest: Dr. Edward Chang, UCSF Weill Institute for Neurosciences, School of Medicine
Disclosures

Dr. Chang and UCSF have intellectual property related to algorithms for BCI, Dr. Chang is a consultant for Synchron

Read Full Episode Description

ANA Investigates the Brain and CPR: Paths to Recovery

Football audiences were shaken on January 2nd when Buffalo Bills safety Damar Hamlin suffered a cardiac arrest after a tackle during a Monday Night Football game. He was resuscitated on the field and then transferred...
Episode Description

Football audiences were shaken on January 2nd when Buffalo Bills safety Damar Hamlin suffered a cardiac arrest after a tackle during a Monday Night Football game. He was resuscitated on the field and then transferred to the University of Cincinnati Medical Center in critical condition. Thus began a waiting period, all too familiar to neurologists, while the world wondered to what extent Mr. Hamlin’s brain would recover. But remarkably, just 4 days later, Mr. Hamlin was able to communicate in writing. He was extubated the following day and discharged home on January 11th. Our guest on today’s podcast, ANA Vice President and Johns Hopkins University neurointensivist Dr. Romer Geocadin, says that Mr. Hamlin’s story should inspire hope... not only for families of survivors of cardiac arrest but also for researchers and physicians. Romer was interviewed by ANA Education Innovation committee Chair and UCSF Neurohospitalist Dr. Megan Richie for this special episode of ANA Investigates.... on cardiac arrest and paths to recovery. Series 4, Episode 3.

Featuring
  • Interviewer/Producer: Dr. Megan Richie, UCSF
  • Guest: Dr. Romer Geocadin, Johns Hopkins
Disclosures

None

Read Full Episode Description

ANA Investigates Myalgic Encephalomyelitis in the Age of Long COVID

The emergence of the syndrome known as long COVID has brought new attention to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). In this episode, we explore the advances in science that may soon lead to answers.
Episode Description

The emergence of the syndrome known as long COVID has brought new attention to myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). On this episode we explore the advances in science that may soon lead to answers.

Featuring
  • Interviewer/Producer: Dr. Megan Richie, UCSF
  • Guest: Dr. Sonya Marshall-Gradisnik, National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Queensland, Australia
  • Guest: Dr. Kiran Thapaliya, National Centre for Neuroimmunology and Emerging Diseases (NCNED), Griffith University, Queensland, Australia
Disclosures

None

Read Full Episode Description

ANA Investigates Disruptive Technologies: Neuroethics Role in Advancing Innovation

Neurotechnology like DBS or transcranial magnetic stimulation have clear benefits in diagnosis and therapy ... what about recent accelerated development from tech entrepreneurs to harness cognitive pathways for everyday tasks?
Episode Description

Neurotechnology like DBS or transcranial magnetic stimulation have clear benefits in diagnosis and therapy and are largely embraced by the medical community. But what about recent accelerated development from tech entrepreneurs to harness cognitive pathways for everyday tasks? This is referred to as brain computer interface technology or BCI. Commercial products such as Neuralink, attempt to implant chips promising to link brain activity with tasks such as accessing phones or cars. This brings up real questions on autonomy, privacy, and medical implications, but is there more to these technological advancements that could provide medical benefit for our patients? We discuss the commercial and medical aspects surrounding BCI technology and the physician and scientist’s role in this rapidly evolving field with Dr. Karen Rommelfanger, the founder and director of the Neuroethics Program at Emory University and now the founder of the world’s first think and DO tank dedicated wholly to neuroethics called the Institute of Neuroethics. She also serves as a member of the BRAIN Initiative’s Neuroethics Working Group and was on the advisory council to the director of the National Institutes of Health (NIH) for BRAIN 2025. Series 4, Episode 1.

Featuring
  • Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
  • Guest: Dr. Karen Rommelfanger, Emory University & Institute of Neuroethics
Disclosures

None

Read Full Episode Description

ANA Investigates Genetics in Epilepsies

Now, making a genetic diagnosis in epilepsy isn’t just important for family planning and prognostication - these diagnoses can also improve patients’ care starting at the moment of diagnosis.
Episode Description

The role of genetics in both pediatric and adult epilepsies is expanding. Now, making a genetic diagnosis in epilepsy isn’t just important for family planning and prognostication - these diagnoses can also improve patients’ care starting at the moment of diagnosis. Our guest today, Ingrid Scheffer, is a leader in gene discovery in epilepsy. Dr. Scheffer is a Laureate Professor of Pediatric Neurology at the University of Melbourne, and she directs the Children's Epilepsy Research Center at Austin Health. She says while there’s still a long way to go before precision medicine is available for the hundreds of known genetic epilepsies, her patients are already benefiting from genetic testing, in many ways. Dr. Scheffer was interviewed by ANA Investigates Producer and epileptologist Dr. Rohit Das of UT Southwestern Medical Center. Series 3, Episode 12.

Featuring
  • Guest: Ingrid Scheffer, AO FRS FAA FAHMS, University of Melbourne
  • Interviewer/Producer: Rohit Das, MD, UT Southwestern
Disclosures

In the past 24 months, Ingrid Scheffer has consulted for Atheneum Partners, Biohaven Pharmaceuticals Inc, Care Beyond Diagnosis, Epilepsy Consortium and Zynerba Pharmaceuticals, has served as an investigator for Anavex Life Sciences, Cerebral Therapeutics, Cerecin Inc, Cereval Therapeutics, Eisai, Encoded Therapeutics, EpiMinder Inc, Epygenyx, ES-Therapeutics, GW Pharma, Marinus, Neurocrine BioSciences, Ovid Therapeutics, Takeda Pharmaceuticals, UCB, Ultragenyx, Xenon Pharmaceutical, Zogenix and Zynerba; received speaker honoraria from Biocodex, BioMarin, Chiesi, Liva Nova and UCB; received funding for travel from Biomarin, Eisai and UCB; and served on scientific advisory boards for Bellberry Ltd, BioMarin, Chiesi, Eisai, Encoded Therapeutics, Knopp Biosciences, Rogcon, Takeda Pharmaceuticals and UCB. Ingrid Scheffer may accrue future revenue on pending patent WO2009/086591: Diagnostic And Therapeutic Methods For EFMR (Epilepsy And Mental Retardation Limited To Females); has a patent for SCN1A testing held by Bionomics Inc and licensed to various diagnostic companies (WO/2006/133508); she has a patent for a molecular diagnostic/therapeutic target for benign familial infantile epilepsy (BFIE) [PRRT2] WO/2013/059884 with royalties paid.

Read Full Episode Description

ANA Investigates Teleneurology and Healthcare Equity

Series 3, Episode 11
Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11.
Episode Description

Equitable tele-neurologic care starts with first identifying disparities, then identifying how to overcome them – learn about both with Dr. Lee Schwamm on the latest ANA Investigates. Series 3, Episode 11.

Featuring
  • Guest: Dr. Lee Schwamm, C Miller Fisher Endowed Chair in Vascular Neurology and the Director of the Center for TeleHealth at Massachusetts General Hospital, Professor of Neurology at Harvard Medical School and Vice President for Digital Patient Experience at the Mass General Bri
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, Director of the UT Teleneurology Division at McGovern Medical School at the University of Texas Health Science Center in Houston
Disclosures
  • Disclosures: None
Read Full Episode Description

*Special Episode* ANA Investigates Potential Fabrication in AD Research Images

Late last month, the journal Science published an investigative report that accused a much-cited publication in Alzheimer’s disease... of fabricating scientific images.
Episode Description

Late last month, the journal Science published an investigative report that accused a much-cited publication in Alzheimer’s disease... of fabricating scientific images. The study under scrutiny was published in Nature in 2006 by Sylvain Lesné and colleagues. It claimed that an amyloid oligomer called Aβ*56 impaired memory in mice. The recent Science report found potential fabrication in the images used in that paper... and concluded that this potential fabrication threatens the amyloid hypothesis in Alzheimer’s disease. Here at ANA Investigates, we decided we needed to ask the experts about that. Their conversation will help us understand the impact of the recent investigative report on the field of Alzheimer’s research. Series 3, Episode 10.

Featuring
  • Guest: Dr. Richard O’Brien, Alzheimer’s researcher, Chair of the Department of Neurology at Duke University
  • Interviewer/Producer: Dr. Erik Roberson, Alzheimer’s researcher, endowed Professor of Neurology, and Director of the Alzheimer’s Disease Center at the University of Alabama at Birmingham
Disclosures

none

 

Read Full Episode Description

ANA Investigates Updates in Autoimmune Encephalitis, part 2, therapeutics

Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis.
Episode Description

Last month on the podcast, we talked about updates in the diagnosis of autoimmune encephalitis. This month we turn to advances in the treatment of autoimmune encephalitis. Treating these conditions has traditionally been practitioner-dependent, and currently no FDA-approved therapies exist. But that’s beginning to change. Series 3, Episode 9.

Featuring
  • Guest: Dr. Maarten Titulaer, Erasmus MC University Medical Center
  • Interviewer/Producer: Dr. Rohini Samudralwar, University of Pennsylvania
Disclosures

Dr. Titulaer disclosed that his institution receives consulting funds form UCB, Viela Bio (Horizon), and CSL Behring, he is the co-investigator on the ExTinguish trial funded in part by Horizon, and a PI IVIG trial funded by CSL Behring.

Read Full Episode Description

ANA Investigates Updates in Autoimmune Encephalitis, part 1, diagnostics

On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis.
Episode Description

On today's episode, Dr. Adeline Goss interviews Dr. Andrew McKeon on updates on diagnostics for part one of a two-part series on autoimmune encephalitis. Series 3, Episode 8.

Featuring
  • Guest: Andrew McKeon,, M.B., B.Ch., M.D., Mayo Clinic College of Medicine and Science
  • Interviewer/Producer: Adeline Goss, MD, Highland Hospital
Disclosures

Dr. McKeon disclosed that he is a consultant for Johnson & Roche Genentech; and receives royalties from Euroimmun

Read Full Episode Description

ANA Investigates TIA

On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7.
Episode Description

On today's episode, we discuss the term "TIA" and the current debate as it pertains to advances in stroke diagnostics that have led some to propose that we retire the term. Series 3, Episode 7.

 

Featuring
  • Guest: Clay, Johnston, MD, PhD, The University of Texas at Austin
  • Interviewer/Producer: Megan Richie, MD, UCSF
Disclosures

Dr. Johnston disclosed research  support from AstraZeneca for the THALES trial.

Read Full Episode Description

ANA Investigates Neurobiology of Burnout

Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University.
Episode Description

Burnt out by talking about burnout? Please join us for a podcast with Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University, to investigate what goes on in the brain that leads to burnout and how this can direct our efforts to reduce burnout. Series 3, Episode 6.

Featuring
  • Guest: Dr. Amy Arnsten, Professor of Neuroscience and Psychology at Yale University
  • Interviewer/Producer: Dr. Amanda Jagolino-Cole, McGovern Medical at the University of Texas Health Science Center in Houston
Read Full Episode Description

ANA Investigates Biomarkers for Alzheimer's Disease

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease.
Episode Description

On today’s show, we’ll focus on the future of biomarkers in Alzheimer’s disease. We know that amyloid beta and tau protein deposit long before patients with Alzheimer’s develop symptoms. If we could use biomarkers to detect this pathology early, and treat patients early, could we prevent the progression to dementia? Our guests today are leaders in the development of biomarkers for Alzheimer’s disease - Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis and Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco. They’ll talk with Dr. Doug Ney of UC Denver about the expanding role of biomarkers in Alzheimer’s prevention and treatment. Series 3, Episode 5.

Featuring
  • Guest: Dr. Suzanne Schindler, Associate Professor of Neurology at Washington University in St. Louis
  • Guest: Dr. Gil Rabinovici, Professor of Neurology and Radiology at the University of California San Francisco
  • Interviewer/Producer: Dr. Doug Ney, UC Denver
Disclosures

Disclosures: Dr. Schindler disclosed that C2N Diagnostics provided data free of cost for her team to analyze. Dr. Rabinovici disclosed that he leads the New IDEAS study and has received research funding from Avid Radiopharmaceuticals, GE Healthcare, Life Molecular Imaging, Genentech; and is on scientific advisory boards for Eisai, J&J, Genentech, Eli Lilly, and Roche.

Read Full Episode Description

ANA Investigates Curing Coma

Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign.
Episode Description

Can coma be “cured”? On this podcast, we talk to Dr. Claude Hemphill and Dr. Romer Geocadin of the Curing Coma Campaign. Series 3, Episode 4 https://www.curingcoma.org/events2/world-coma-day

Below are articles the guests of this podcast wished to share with the listeners:

 

 

<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/22155224/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/000000/" height="90" width="100%" scrolling="no"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>

Featuring
  • Guest: Romer Geocadin, MD, Johns Hopkins University
  • Guest: Claude Hemphill, MD, University of California San Francisco
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

none

Read Full Episode Description

ANA Investigates Basilar Artery Stroke

Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients.
Episode Description

Treatment of stroke has changed dramatically in the past decade, with the advent of perfusion imaging and an expanded time window for mechanical thrombectomy. Thrombectomy is now standard of care for eligible patients. But while data clearly supports the use of thrombectomy for certain patients with anterior circulation strokes, the benefit of thrombectomy for patients with basilar artery occlusions remains unproven. Today we’ll talk to a vascular neurologist and a neurointerventional surgeon who are trying to better define which patients with basilar artery occlusion may benefit from thrombectomy -- and which patients may not. Series 3, Episode 3. 

Featuring
  • Guest: Dr. Carlo Cereda, vascular neurologist, head of the EOC Comprehensive Stroke Center at the Neurocenter of Southern Switzerland and Faculty of Biomedical Sciences, Università della Svizzera Italiana in Lugano
  • Guest: Dr. Jeremy Heit, Assistant Professor of Radiology and of Neurosurgery and the interim Chief of Neuroradiology at Stanford University
  • Interviewer/Producer: Dr. Michelle Johansen, Assistant Professor of Neurology, Johns Hopkins Medicine
Disclosures

Disclosures: Dr. Heit disclosed that he consults for Medtronic and MicroVention, and consults and is a member of medical and scientific advisory board for iSchemaView, Inc., and Dr. Cereda disclosed that he is a advisory board for iSchemaView, Inc.

Read Full Episode Description

ANA Investigates FND

On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor.
Episode Description

On today’s show we’ll focus on functional neurological disorder, or FND -- a wide range of conditions including non-epileptic seizures and functional weakness, dystonia and tremor. These conditions are common and can cause serious disability. But what are these conditions, exactly? What have functional neuroimaging and other tools taught us about their pathophysiology, diagnosis, and treatment? Series 3, Episode 2.

Featuring
  • Guest: Dr. Sara Finkelstein, neurologist and specialist in functional neurological disorder at Massachusetts General Hospital
  • Interviewer/Producer: Dr. Adeline Goss, Highland Hospital
Disclosures

none

Read Full Episode Description

ANA Investigates Neurostimulation

Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time.
Episode Description

Some patients with medically refractory epilepsy are offered surgeries to implant devices that electrically stimulate the nervous system and actually modulate neural networks over time. On this episode of ANA Investigates, Dr. Vikram Rao of the UCSF Weill Institute for Neurosciences discusses how these neurostimulation devices can reduce seizure burden, along with a range of other potential benefits.‌ Series 3, Episode 1.

Featuring
  • Guest: Dr. Vikram Rao, epileptologist and Associate Professor of Neurology at the UCSF Weill Institute for Neurosciences
  • Interviewer/Producer: Dr. Rohit Das, epileptologist at UT Southwestern Medical Center‌‌
Disclosures

Dr. Rao disclosed the following relevant relationships for CME purposes: NeuroPace-Consultant; LivaNova-Scientific Advisory Board

Read Full Episode Description